Stay updated on IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; 'Back to Top' link removed. This is a minor maintenance update with no substantive content changes.SummaryDifference0.6%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.6%
- Check17 days agoChange DetectedThe web page has been updated to include a new facility name and location, along with several updates to study statuses and recruitment timelines. Notably, the date for a study has been changed to August 28, 2025.SummaryDifference33%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference4%
Stay in the know with updates to IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.